Clinical trials
Overweight trials in Brazil
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
88 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 8 |
| 2026 | 21 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Recruiting | 21 |
| Unknown status | 10 |
| Active, not recruiting | 7 |
| Not yet recruiting | 6 |
| Withdrawn | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 21 |
| Novo Nordisk A/S | 6 |
| University of Sao Paulo | 6 |
| Hospital de Clinicas de Porto Alegre | 5 |
| Federal University of Health Science of Porto Alegre | 4 |
| Federal University of Minas Gerais | 4 |
| University of Sao Paulo General Hospital | 4 |
| Amgen | 2 |
| AstraZeneca | 2 |
| Eurofarma Laboratorios S.A. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Overweight | 88 |
| Obesity | 82 |
| Diabetes Mellitus, Type 2 | 12 |
| Diabetes Mellitus | 6 |
| Nutrition Disorders | 5 |
| Weight Loss | 5 |
| Sleep Apnea, Obstructive | 4 |
| Insulin Resistance | 3 |
| Prediabetic State | 3 |
| Diabetes Mellitus, Type 1 | 2 |
Trials
Showing 51 to 75 of 88. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.